AI Article Synopsis
- A systematic review and meta-analysis was conducted to evaluate the effectiveness of proton beam therapy (PBT) for treating hepatocellular carcinoma (HCC), focusing on recent data from various medical databases.
- The analysis included 1,858 HCC patients from 22 studies between 2004 and 2023, revealing a high local progression-free survival rate of 88% at 3 years and 86% at 5 years, with low rates of severe hepatic toxicity.
- The findings suggest that PBT offers favorable long-term outcomes for HCC patients with minimal side effects, but further research is needed to determine which specific patient groups benefit the most from this treatment.
Article Abstract
Backgrounds/aims: Although access to proton beam therapy (PBT) is limited worldwide, its use for the treatment of hepatocellular carcinoma (HCC) is gradually increasing with the expansion of new facilities. Therefore, we conducted a systematic review and metaanalysis to investigate the updated evidence of PBT for HCC.
Methods: The MEDLINE, EMBASE, Cochrane Library, and Web of Science databases were systematically searched for studies that enrolled patients with liver-confined HCC that were treated with PBT for a cure up to February 2024.
Results: A total of 1,858 HCC patients receiving PBT from 22 studies between 2004 and 2023 were selected for this meta-analysis. The median proportion of Child-Pugh class A was 86% (range, 41-100), and the median tumor size was 3.6 cm (range, 1.2-9.0). The median total dose ranged from 55 GyE to 76 GyE (median, 69). The pooled rates of 3- and 5-year local progression-free survival after PBT were 88% (95% confidence interval [CI], 85-91) and 86% (95% CI, 82-90), respectively. The pooled 3- and 5-year overall rates were 60% (95% CI, 54-66) and 46% (95% CI, 38-54), respectively. The pooled rates of grade 3 hepatic toxicity, classic radiationinduced liver disease (RILD), and non-classic RILD were 1%, 2%, and 1%, respectively.
Conclusions: The current study supports PBT for HCC and demonstrates favorable long-term survival and low hepatic toxicities compared with other published studies on other radiotherapy modalities. However, further studies are needed to identify the subgroups that will benefit from PBT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449586 | PMC |
| http://dx.doi.org/10.17998/jlc.2024.06.26 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Defining the Optimal Dose for 3-Dimensional Conformal Accelerated Partial Breast Irradiation: 15-Year Follow-Up of a Dose-Escalation Trial.
Int J Radiat Oncol Biol Phys
January 2025
Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Purpose: Randomized trials have demonstrated similar local tumor control in patients treated with accelerated partial-breast irradiation (APBI) compared with whole-breast irradiation. However, the optimal APBI dose for maximizing tumor control and minimizing toxicity is uncertain.
Methods And Materials: We enrolled patients ≥18 years of age with grade 1 or 2 ductal carcinoma in situ or stage I invasive breast cancer and resection margins ≥2 mm between 2003 and 2011 to a sequential dose-escalation trial using 3-dimensional conformal external beam APBI giving twice daily 4 Gy fractions with total doses of 32 Gy, 36 Gy, and 40 Gy.
Evaluating Proton Versus Photon Therapy: A Call for Nuanced Decision-Making.
J Med Radiat Sci
January 2025
Royal Adelaide Hospital, Adelaide, South Australia, Australia.
This letter critically evaluates the conclusions drawn by Li et al. (https://doi.org/10.
View Article and Find Full Text PDFCharacterisation of the HollandPTC R&D proton beamline for physics and radiobiology studies.
Phys Med
January 2025
Department of Research and Development, Holland Proton Therapy Centre Delft, Delft, The Netherlands.
HollandPTC is an independent outpatient center for proton therapy, scientific research, and education. Patients with different types of cancer are treated with Intensity Modulated Proton Therapy (IMPT). Additionally, the HollandPTC R&D consortium conducts scientific research into the added value and improvements of proton therapy.
View Article and Find Full Text PDFAnaesthesia for paediatric radiotherapy: A narrative review.
Anaesthesia
January 2025
The Christie NHS Foundation Trust, Manchester, UK.
Introduction: Radiotherapy is currently used in approximately one-third of children with cancer. Treatments are typically received as weekday outpatient appointments over 3-6 weeks. The treatment is painless but requires a still, co-operative patient who can lie alone in set positions, facilitated by the use of immobilisation devices, for up to 1 h.
View Article and Find Full Text PDFEndocrine dysfunction in long-term survivors of pediatric head and neck rhabdomyosarcoma.
Eur J Endocrinol
January 2025
Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Objective: Survivors of pediatric head and neck rhabdomyosarcoma (HNRMS) are at risk of developing endocrinopathies following local treatment, resulting from radiation damage to the pituitary gland, hypothalamus, or thyroid gland, often at a young age. Our aim was to determine the prevalence of endocrine dysfunction in long-term HNRMS survivors and compare the prevalence of anterior pituitary insufficiency (API) among different local treatment strategies: external beam radiation with photons, external beam radiation with protons, microscopically radical surgery combined with external irradiation, and macroscopic radical surgery combined with brachytherapy.
Design And Methods: Head and neck rhabdomyosarcoma survivors treated between 1993 and 2017, with ≥2 years of follow-up, without recurrent disease or secondary malignancy were eligible for this study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!